期刊文献+

Omi/HtrA2基因启动子-958C/G多态性与帕金森病的相关性研究

Correlative Study of Omi/HtrA2 gene promoter -958C/G polymorphism in Parkinson' s disease
原文传递
导出
摘要 目的探讨Omi/HtrA2基因启动子-958C/G单核苷酸多态性(SNP)与帕金森病(PD)的关系。方法采用病例一对照研究,选择56例PD患者(病例组)和109例健康体检者(对照组)为对象,应用聚合酶链反应一限制性酶切片段长度多态性分析方法(PCR—RFLP)检测Omi/HtrA2基因启动子958C/G单核苷酸多态性,并分析其基因型及等位基因频率在正常人群及PD患者中的分布特点。结果Omi/HtrA2基因启动子SNP-958C/G在病例组中C等位基因频率为75.0%,对照组为84.4%,两组比较差异有统计学意义(P〈0.05);病例组CC基因型为53.6%,对照组为69.7%,两组比较差异有统计学意义(P〈0.05)。结论Omi/HtrA2基因启动子SNP一958C/G与PD相关,C等位基因及CC基因型对PD可能是保护性因素。 Objective To investigate the frequency distribution of single-nucleotide polymorphisms(SNP) of Omi/HtrA2 gene promoter -958C/G, and the relationship between these polymorphism and Parkinson' s disease (PD). Methods By using a case-control method, 56 PD patients ( the case group) and 109 healthy controls( the control group) were selected in the study. The SNP of -958C/G of Omi/HtrA2 gene was identified by the polymerase chain reaction(PCR) and restriction fragment length polymorphism(RFLP) ,and genotype and allele frequency distributions in normal people and PD patients were analyzed. Results The C allele frequency of Omi/HtrA2 gene SNP-958C/G was 75.0% in the case group, and which in the control group was 84.4%. The difference was significant( P 〈 0.05 ) ;In PD, CC genotyping frequencies was 53.6%, and that in controls was 69.7%. The difference was also significant (P 〈 0.05). Conclusion Omi/HtrA2 gene SNP-958C/G was associated with PD, C allele and CC genotype might be the protective factor of PD patients.
出处 《临床内科杂志》 CAS 2012年第4期243-245,共3页 Journal of Clinical Internal Medicine
基金 广东省医学科研基金资助项目A2007453
关键词 Omi/HtrA2基因 单核苷酸多态性 启动子 帕金森病 Omi/HtrA2 Single nucleotide polymorphism Promoter Parkinson' s disease
  • 相关文献

参考文献11

  • 1Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci ,2000,23:298-304.
  • 2Hegde R, Srinivasula SM, Zhang Z, et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem ,2002,277:432-438.
  • 3Jones JM, Datta P ,Srinivasula SM, et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature, 2003,425 : 721-727.
  • 4中华医学会神经病学分会帕金森病及运动障碍学组.中华神经科杂志,2006,6:408-412.
  • 5Faccio L, Fusco C, Chen A, et al. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem,2000, 275:2581-2588.
  • 6Gray CW, Ward RV, Karran E, et al. Characterization of human HtrA2, a novel serine protease involved in the mammaliancellular stress response. Eur J Biochem,2000,267:5699-5710.
  • 7Li B, Hu Q, Wang H, et al. Omi/HtrA2 is a positive regulator of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. Cell Death Differ,2010,17 : 1773-1784.
  • 8Radke S, Chander H, Sehafer P, et al. Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease omi. J Biol Chem,2008,283 : 12681-12685.
  • 9Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/Htra2 in Parkinson' s disease. Human Molecular Genetics ,2005,14:2099-2111.
  • 10Bogaerts V, Nuytemans K, Reumers J, et al. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat ,2008,29:832-840.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部